Kidney Cancer, Lymphomas, Positron Emission Tomography
Conditions
Brief summary
The aim of this study was to establish and optimize the \[18F\]RCCB6 and \[68Ga\]Ga-NOTA-RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in renal cancer (especially clear cell renal cell carcinoma) and lymphoma was evaluated.
Interventions
RADIATION[18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
Sponsors
Huashan Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Be between 18 and 65 years of age and of either sex. 2. Affected with renal cancer or lymphoma confirmed by puncture or surgical pathology. 3. Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver. 4. Willingness and ability to cooperate with all programs of this study.
Exclusion criteria
* Subjects meeting any of the following criteria will be excluded from the study: 1. Severe hepatic and renal insufficiency; 2. Targeted therapy prior to radiotherapy or PET/CT scan. Renal function: serum creatinine less than or equal to the upper limit of the normal range; 3. Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range. 4. History of serious surgery in the last month. 5. Those who have participated in other clinical trials during the same period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete PET imaging | 90mins from time of injection | 1\. Establishment and optimization of imaging method for \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 PET/CT imaging. 2. Evaluating the sensitivity and specificity of using \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 PET/CT in diagnosing renal cell carcinoma (especially metastatic clear cell renal carcinoma) and lymphoma. |
Countries
China
Contacts
Primary ContactYihui Guan, MD
Outcome results
None listed